P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation

類似資料

• Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells
  著者:: Laurin, David, 等
  出版事項: (2010)
• Role of Immunomodulation of BCG Therapy on AML Remission
  著者:: Kennedy, Alice, 等
  出版事項: (2021)
• Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
  著者:: Tratkiewicz, J A, 等
  出版事項: (1990)
• Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
  著者:: Gangal, S. G., 等
  出版事項: (1979)
• BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance
  著者:: Weiland, J, 等
  出版事項: (2016)